Onsdag 30 Oktober | 09:27:41 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-01 07:00 Kvartalsrapport 2024-Q3
2024-09-09 - X-dag ordinarie utdelning AKBM 45.00 NOK
2024-09-03 - Extra Bolagsstämma 2024
2024-07-12 - Kvartalsrapport 2024-Q2
2024-04-26 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning AKBM 0.00 NOK
2024-04-16 - Årsstämma
2024-02-14 - Bokslutskommuniké 2023
2023-11-01 - Kvartalsrapport 2023-Q3
2023-07-14 - Kvartalsrapport 2023-Q2
2023-04-28 - Kvartalsrapport 2023-Q1
2023-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2023-04-20 - Årsstämma
2023-02-15 - Bokslutskommuniké 2022
2022-11-01 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-04-29 - Kvartalsrapport 2022-Q1
2022-04-21 - X-dag ordinarie utdelning AKBM 0.00 NOK
2022-04-20 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-07-14 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-03-15 - X-dag ordinarie utdelning AKBM 0.00 NOK
2021-03-12 - Årsstämma
2021-02-16 - Bokslutskommuniké 2020
2020-10-30 - Kvartalsrapport 2020-Q3
2020-07-15 - Kvartalsrapport 2020-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHandel & varor
IndustriDagligvaror
Aker BioMarine är verksamma inom bioteknik. Bolaget är specialiserade inom utveckling av kostillskott. Produktportföljen är bred och inkluderar exempelvis omega-3 olja, näringstillskott för djur, samt proteintillskott för fiskeodling. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Kunderna består av både privata aktörer samt grossister. Aker BioMarine grundades år 2006 och har sitt huvudkontor i Oslo.
2023-05-09 22:58:12
9 May 2023: Aker BioMarine ASA (the "Company") has renewed its offer of new
shares to employees in the Company and its Norwegian subsidiaries on similar
terms as for 2022 (the "Employee Share Purchase Program"). The deadline for
acceptance of the offer in the Employee Share Purchase Program expired today, on
9 May 2023, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been
set to approximately NOK 29,81 (the "Offer Price"). The Offer Price is based on
the volume-weighted average share price for the Company's shares on the Oslo
Stock Exchange during the last five trading days prior to, and including, the
last day of the application period, with a discount of 20%. Any shares acquired
in the Employee Share Purchase Program will be subject to a lock-up period of
two years, and the reduced offer price shall reflect the value-reducing effect
of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the
board of directors of the Company has allocated a total of 35,015 new shares to
the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation
granted to it by the annual general meeting held on 20 April 2023, resolved to
increase the share capital of the Company with NOK 210 090, by issuance of
35,015 new shares, each with a nominal value of NOK 6.00, at a subscription
price equal to the Offer Price. The Program Shares comprise approximately 0.04%
of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian
Register of Business Enterprises (Nw.: Foretaksregisteret), the new share
capital of the Company will be NOK 526 036 488, divided into 87 672 748 shares,
each with a nominal value of NOK 6.00.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

For further information, please contact
Katrine Klaveness, CFO
Mobile: +47 991 58 915
Email: Katrine.Klaveness@akerbiomarine.com

About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for pharma, consumer health and
wellness as well as animal nutrition. The company has a strong position in its
industry and is the world's leading supplier of krill, the natural, powerful and
health promoting source of nutrients from the pristine waters of Antarctica.
Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is
available at www.akerbiomarine.com.